Compare · MDLN vs VVOS
MDLN vs VVOS
Side-by-side comparison of Medline Inc. (MDLN) and Vivos Therapeutics Inc. (VVOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and VVOS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 10017.6x VVOS ($4.8M).
- Over the past year, MDLN is down 11.8% and VVOS is down 95.5% - MDLN leads by 83.7 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 4 for VVOS).
- MDLN has more recent analyst coverage (25 ratings vs 1 for VVOS).
- Company
- Medline Inc.
- Vivos Therapeutics Inc.
- Price
- -
- -
- Market cap
- $48.08B
- $4.8M
- 1M return
- +11.97%
- -28.14%
- 1Y return
- -11.77%
- -95.45%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2020
- News (4w)
- 7
- 4
- Recent ratings
- 25
- 1
Vivos Therapeutics Inc.
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest VVOS
- SEC Form 8-K filed by Vivos Therapeutics Inc.
- Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
- Vivos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
- SEC Form 4 filed by Director Sokolow Leonard J
- SEC Form 4 filed by Director Johnson Gregg C
- Chief Executive Officer Huntsman Ronald Kirk acquired $50,000 worth of Preferred Stock (85,910 units at $0.58) (SEC Form 4)
- Amendment: Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Vivos Therapeutics Announces Material Debt Reduction
- Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits